NeuroDerm announces plans to price initial public offering of shares

Jefferies and Cowen are bookrunners; Oppenheimer, Roth Capital assist

By Devika Patel

Knoxville, Tenn., Sept. 15 – NeuroDerm Ltd. will price its initial public offering of ordinary shares with a 30-day greenshoe, according to a Form F-1 filed Monday with the Securities and Exchange Commission.

Jefferies and Cowen and Co. are the joint bookrunning managers. Oppenheimer & Co. and Roth Capital Partners are the co-managers.

Proceeds will be used for product development, research, working capital and for general corporate purposes.

The clinical-stage pharmaceutical company is based in Rehovot, Israel. It intends to list its stock on the Nasdaq under the symbol “NDRM.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.